![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Takeda to Purchase Maverick for $525 Million to Boost T-Cell Therapy Pipeline
Takeda to Purchase Maverick for $525 Million to Boost T-Cell Therapy Pipeline
![Acquires -Acquired](https://www.fdanews.com/ext/resources/test/Device_Images6/Acquired-Acquires.gif?t=1604445798&width=430)
Takeda Pharmaceutical is expanding its immune-oncology portfolio by acquiring Brisbane, Calif.-based Maverick Therapeutics for $525 million.
The Japanese drugmaker will gain access to Maverick’s COBRA T-cell engaging platform and development pipeline. T‐cell engager technology is designed to treat cancers by connecting patients’ T-cells to cancer cells.
The purchase follows a multiyear partnership Takeda and Maverick forged in 2017 to develop new T-cell engager therapies. Under the terms of the acquisition, Maverick will receive an undisclosed upfront payment and potential milestone-based payments totaling $525 million.
Upcoming Events
-
21Oct